Retro-X[™] Concentrator Protocol-at-a-Glance (PT5063-2)

A. Summary

The Retro-X Concentrator (Cat. Nos. 631455 & 631456) provides a fast and simple method for concentrating retroviral stocks. Concentration is achieved by mixing a retroviral supernatant with this concentration reagent, followed by an incubation step and centrifugation in a standard centrifuge. The process is easily scaled up to accomodate larger supernatant volumes. No ultracentrifugation is required. The Retro-X Concentrator is designed for use with all retroviral supernatants, including all of Clontech's Retro-X vectors. Using this reagent increases vector titer (IFU/mI) by 1–2 logs in a reasonable amount of time with minimal loss of material.

B. Protocol

Viral supernatant is collected from your virus-producing cell line and centrifuged to remove cells and debris. It is then mixed with the Retro-X Concentrator and incubated overnight at 4°C. The mixture is then centrifuged at low speed to obtain a high-titer virus-containing pellet which can then easily be resuspended and used for transduction of your intended target cells.

 Harvest the retrovirus-containing supernatants. (Caution: supernatants contain live retrovirus.) Pool similar stocks, if desired. Centrifuge briefly (500 x g for 10 min) or filter through a 0.45 µm filter.

NOTE: If filtering, use only cellulose acetate or polyethersulfone (PES) (low protein binding) filters. Do not use nitrocellulose filters. Nitrocellulose binds surface proteins on the retroviral envelope and destroys the virus.

2. Transfer clarified supernatant to a sterile container and combine 1 volume of Retro-X Concentrator with 3 volumes of clarified supernatant. Mix by gentle inversion. Larger volumes may be accomodated through the use of larger (i.e., 250 ml or 500 ml) centrifuge tubes. It is recommended to start with at least 10 ml or more of viral supernantant if the viral titer is expected or known to be low (~10⁵ IFU/ml).

NOTE: For easy calculation of the amount of Retro-X Concentrator to use, simply measure the amount of viral supernatant to be concentrated, divide by 3 and add the resulting amount of Retro-X Concentrator to your viral supernatant.

- 3. Incubate mixture overnight at 4°C.
- 4. Centrifuge sample at 1,500 x g for 45 minutes at 4°C. After centrifugation, an off-white pellet will be visible.
- 5. Carefully remove supernatant, taking care not to disturb the pellet. Residual supernatant can be removed with either a pipette tip or by brief centrifugation at 1,500 x g.
- 6. Gently resuspend the pellet in 1/10 to 1/100th of the original volume using complete DMEM, PBS, or TNE. The pellet can be somewhat sticky at first, but will go into suspension quickly.
- 7. Immediately titrate sample or store at –70°C in single-use aliquots.

NOTE: For fast determination, the Retro-X qRT-PCR Titration Kit (Cat. No. 631451) directly quantifies the viral genomes in your virus stock, which is much faster and often more useful than antibiotic selection. Since it exploits conserved regions contained in most retroviral vectors, all particles, regardless of expression features (promoters, cDNAs, etc.), can be quantified.

Clon**tech**

United States/Canada 800.662.2566 Asia Pacific +1.650.919.7300 Europe +33.(0)1.3904.6880 Japan +81.(0)77.543.6116

Clontech Laboratories, Inc. ATakara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Clontech, the Clontech Logo and all other trademarks are property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2009 Clontech Laboratories, Inc.